Foghorn Therapeutics Inc. (FHTX) — SEC Filings
Foghorn Therapeutics Inc. (FHTX) — 48 SEC filings. Latest: 10-Q (May 7, 2026). Includes 30 8-K, 6 10-Q, 3 SC 13G/A.
View Foghorn Therapeutics Inc. on SEC EDGAR
Overview
Foghorn Therapeutics Inc. (FHTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 30, 2026: Foghorn Therapeutics Inc. filed a Definitive Additional Materials (DEFA14A) on April 30, 2026. This filing relates to the solicitation of proxies for a special meeting of stockholders. The company is headquartered at 500 Technology Square, Suite 700, Cambridge, MA 02139.
Sentiment Summary
Across 48 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 44 neutral, 2 mixed. The dominant filing sentiment for Foghorn Therapeutics Inc. is neutral.
Filing Type Overview
Foghorn Therapeutics Inc. (FHTX) has filed 6 10-Q, 30 8-K, 1 ARS, 1 DEFA14A, 1 S-8, 2 DEF 14A, 1 10-K, 3 SC 13G/A, 2 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (48)
Risk Profile
Risk Assessment: Of FHTX's 35 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $21.7M |
| Net Income | $-52.6M |
| EPS | $-0.84 |
| Debt-to-Equity | N/A |
| Cash Position | $180.3M |
| Operating Margin | N/A |
| Total Assets | $204.96M |
| Total Debt | $294.62M |
Key Executives
- David Epstein
- David R. Johnson
- Dr. Jeffrey W. Albeson
- Jeffrey J. Astrachan
- Noubar Afeyan
- Scott Biller
- Thomas J. Lynch
- Michael Mendelsohn
- Dr. Jeffrey W. Allen
- Dr. Adrian S. Law
- Abigail P. Johnson
Industry Context
Foghorn Therapeutics operates in the highly competitive biotechnology sector, focusing on oncology. The industry is characterized by significant R&D investment, long development cycles, and reliance on scientific innovation. Key trends include advancements in targeted therapies, immuno-oncology, and the increasing importance of strategic partnerships for drug development and commercialization.
Top Tags
financials (7) · 8-K (6) · regulatory-filing (5) · corporate-governance (5) · 8-k (5) · disclosure (4) · sec-filing (3) · regulation-fd (3) · Biotechnology (3) · corporate-disclosure (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| S-8 Form Size | 60294 | Size of the primary S-8 registration document in bytes. |
| Complete Submission Text File Size | 224928 | Size of the complete submission text file in bytes. |
| SEC File Number | 001-39634 | Identifier for Foghorn Therapeutics' SEC filings. |
| Fiscal Year End | 1231 | Indicates the end of Foghorn Therapeutics' fiscal year. |
| Commission File Number | 001-39634 | Identifies the company's SEC filing history. |
| IRS Employer Identification No. | 47-5271393 | Company's tax identification number. |
| Net Loss | $52.6M | for the nine months ended September 30, 2025, an improvement from $67.1M in 2024 |
| Accumulated Deficit | $610.8M | as of September 30, 2025, indicating significant historical losses |
| Collaboration Revenue | $21.7M | for the nine months ended September 30, 2025, up from $19.7M in 2024 |
| Research and Development Expenses | $63.4M | for the nine months ended September 30, 2025, a decrease from $74.0M in 2024 |
| Cash, Cash Equivalents, and Marketable Securities | $180.3M | as of September 30, 2025, down from $243.7M at December 31, 2024 |
| Cash Runway | 12 months | expected duration of current cash to fund operations |
| Common Stock Shares Outstanding | 56,551,289 | as of October 31, 2025 |
| Q2 2025 Collaboration Revenue | $16.7M | Increased 63.7% from $10.2M in Q2 2024 |
| YTD 2025 Collaboration Revenue | $32.1M | Increased 59.7% from $20.1M in YTD 2024 |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, but potentially fluctuating, stake in Foghorn Therapeutics Inc. over the next year.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"medium"}
- {"claim":"FHTX stock price will experience volatility due to the new disclosures.","entity":"FHTX","targetDate":"2024-02-15","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Foghorn Therapeutics Inc. (FHTX)?
Foghorn Therapeutics Inc. has 48 recent SEC filings from Jan 2024 to May 2026, including 30 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of FHTX filings?
Across 48 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 44 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Foghorn Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Foghorn Therapeutics Inc. (FHTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Foghorn Therapeutics Inc.?
Key financial highlights from Foghorn Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for FHTX?
The investment thesis for FHTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Foghorn Therapeutics Inc.?
Key executives identified across Foghorn Therapeutics Inc.'s filings include David Epstein, David R. Johnson, Dr. Jeffrey W. Albeson, Jeffrey J. Astrachan, Noubar Afeyan and 6 others.
What are the main risk factors for Foghorn Therapeutics Inc. stock?
Of FHTX's 35 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Foghorn Therapeutics Inc.?
Recent forward-looking statements from Foghorn Therapeutics Inc. include guidance on {"claim":"FMR LLC will maintain a significant, but potentially fluctuating, stake in Foghorn Therapeutics Inc. over the and 1 other predictions.